Ipsen’s ultra-rare bone disease drug flops in Phase II trial
Ipsen’s fidrisertib has failed to show meaningful benefit above placebo in a Phase II trial in patients with fibrodysplasia ossificans …
Post
-
-
Psyence gains HREC nod to use PsyLabs’ psilocybin in adjustment disorder trial
Psyence BioMed has received formal approval from the Bellberry Human Research Ethics Committee (HREC), Australia, to use psychedelic active pharmaceutical …
-
Altimmune reports positive topline results from IMPACT Phase IIb trial
Altimmune has announced positive topline results from the IMPACT Phase IIb trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor …
-
Takeda to seek approval of plaque psoriasis pill on Phase III trial data
Takeda’s once-daily oral plaque psoriasis (PsO) drug has met all its endpoints in two pivotal trials, with the company set …
-
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Eli Lilly’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA), orforglipron, has proven its efficacy as a maintenance therapy in patients …
-
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Eli Lilly’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA), orforglipron, has proven its efficacy as a maintenance therapy in patients …
-
Soligenix reports Phase IIa SGX945 trial data for Behçet’s disease
Soligenix has reported positive data from its Phase IIa trial of SGX945 (dusquetide) for the treatment of Behçet's disease. The proof-of-concept …
-
New report showcases AI breakthroughs, diversity, and innovation for 2026
The brand-new edition of the 2026 Clinical Research Report examines key therapy areas and deep dives into the latest advances …
-
Qihan Biotech begins subject dosing in Phase I/IIa study of QT-019B for rSLE
Qihan Biotech has commenced patient dosing in a Phase I/IIa clinical trial of the allogeneic chimeric antigen receptor T-cell (CAR-T) …
-
Clinical Trials Arena Excellence Awards 2025: SubjectWell
SubjectWell, founded in 2012 to connect patients with clinical trials, now positions itself as a global Patient Experience Platform serving …
-
Galderma’s Nemluvio shows itch reduction in 48 hours
Galderma’s dermatology monoclonal antibody (mAb) Nemluvio (nemolizumab) has shown proof of improving symptoms of atopic dermatitis (AD) and prurigo nodularis …
-
Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs
Author: Manny Vazquez, Senior Director Clinical Data Strategy, Veeva The number of data points collected in clinical trials has tripled over …
-
Padcev-Keytruda notches another Phase III win in bladder cancer
A combination of Pfizer and Astellas’ Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) has offered significant improvements to patient outcomes …
-
Hutchmed begins Phase I HMPL-A251 clinical development programme
Hutchmed has commenced its worldwide Phase I clinical development programme for a first-in-class phosphoinositide 3-kinase (PI3K) / phosphoinositide 3-kinase-related protein …
-
England sees increase in influenza hospitalisations
According to statistics from the National 'Flu and Covid-19 Surveillance Report published by the UK's National Health Service (NHS) on …
